Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Sirolimus

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Sirolimus, Rapamune,Rapamycin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Palvella Completes Pre-NDA for QTORIN in Lymphatic Malformations
    Palvella Completes Pre-NDA for QTORIN in Lymphatic Malformations

    03 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/03/3305944/0/en/palvella-therapeutics-announces-completion-of-fda-pre-nda-meeting-for-qtorin-rapamycin-in-microcystic-lymphatic-malformations.html

    GLOBENEWSWIRE
    03 Jun 2026
    Share Share
    Advanced NanoTherapies Raises 31M for Dual-Drug Vascular Platform
    Advanced NanoTherapies Raises 31M for Dual-Drug Vascular Platform

    02 Jun 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/advanced-nanotherapies-secures-over-31m-series-b-to-deliver-first-of-its-kind-dual-drug-paclitaxel-and-sirolimus-nanoparticle-coated-balloon-platform-for-vascular-treatment-302786565.html

    PR NEWSWIRE
    02 Jun 2026
    Share Share
    Palvella Presents QTORIN Data for Rare Vascular Malformations
    Palvella Presents QTORIN Data for Rare Vascular Malformations

    20 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/20/3298897/0/en/Palvella-Therapeutics-Presents-New-SELVA-and-TOIVA-Data-at-the-2026-International-Society-for-the-Study-of-Vascular-Anomalies-World-Congress-Supporting-QTORIN-Rapamycin-as-a-Potent.html

    GLOBENEWSWIRE
    20 May 2026
    Share Share
    Reflow Medical Reports 6-Month DEEPER CORONARY Study Results
    Reflow Medical Reports 6-Month DEEPER CORONARY Study Results

    20 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260520334491/en/Reflow-Medical-Reports-Six-Month-Results-from-DEEPER-CORONARY-Study-of-Spur-Elute-Stent

    BUSINESSWIRE
    20 May 2026
    Share Share
    Orchestra BioMed Receives $15M Investment from Ligand
    Orchestra BioMed Receives $15M Investment from Ligand

    06 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/06/3288787/0/en/orchestra-biomed-receives-15-million-investment-from-ligand-under-previously-announced-strategic-financing-agreement.html

    GLOBENEWSWIRE
    06 May 2026
    Share Share
    Palvella Initiates Phase2 For QTORIN Rapamycin for Angiokeratomas
    Palvella Initiates Phase2 For QTORIN Rapamycin for Angiokeratomas

    04 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/04/3286595/0/en/palvella-therapeutics-announces-first-patients-dosed-in-phase-2-lotu-trial-of-fast-track-designated-qtorin-rapamycin-for-clinically-significant-angiokeratomas.html

    GLOBENEWSWIRE
    04 May 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.